Llach, MassryS.G.On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency.J Clin Endocrinol Metab1985; 61: 601–6.
2.
SherrardD.J., HerczG., PeyY.. The spectrum of bone disease in end-stage renal failure-An evolving disorder.Kidney Int1993; 43: 436–42.
3.
MallucheH., FaugereM.C.Renal bone disease 1990: an unmet challenge for the nephrologist.Kidney Int1990; 38: 193–211.
4.
SlatopolskyE., MartinK., HruskaK.Parathyroid hormone metabolism and its potential as a uremic toxin.Am J Physiol1980; 239: F1–F12.
5.
NishizawaY., ShojiT., KawagishiT., MoriiH.Atherosclerosis in uremia: possibile roles of hyperparathyroidism and intermediate density lipoprotein accumulation.Kidney Int1997; 62: S90–2.
6.
GoldsmithD.J., CovicA.A., VenningM.C., AckrillP.Blood pressure reduction after parathyroidectomy for secondary hyperparathyroidism: further evidence implicating calcium homeostasis in blood pressure regulation.Am J Kidney Dis1996; 27: 819–25.
7.
ChristiansenC., ChristensenM.S., MelsenF., RodbroP., DeLucaH.F.Mineral metabolism in chronic renal failure with special reference to serum concentrations of 1.25 (OH)2D3 and 2.25(OH)2D3.Clin Nephrol1981; 15: 18–22.
8.
WilsonL., FelsenfeldA., DreznerM.K., LlachF.Altered divalention metabolism in early renal failure: role of 1.25(OH)2D.Kidney Int1985; 27: 563–73.
9.
MessaP.Vallone C, Mioni G, et al. Direct in vivo assessment of parathyroid hormone calcium relationship curve in renal patients.Kidney Int1994; 46: 1713–20.
10.
FukagawaM., KanameS.Y., IgarashiT., OgataE., KurokawaK.Regulation of parathyroid hormone synthesis in chronic renal failure in rats.Kidney Int1991; 39: 874–81.
11.
KorkorA.B.Reduced binding of [3H]1.25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure.N Engl J Med1987; 316: 1573–7.
12.
MerkeJ.Hugel U, Zlotkowsky A et al. Diminished parathyroid 1.25(OH)2D3 receptor in experimental uremia.Kidney Int1987; 32: 350–3.
13.
PatelS.R., Qiong KeH., HsuC.H.Regulation of calcitriol receptor and its mRNA in normal and renal failure rats.Kidney Int1994; 45: 1020–7.
14.
BrownA.J., DussoA., Lopez-HilkerS., Lewis-FinchJ., GroomsP., SlatopolskyE.1.25(OH)2D3 receptors are decreased in parathyroid glands from chronic uremic dogs.Kidney Int1989; 35: 19–23.
15.
FukudaN., TanakaH., TominagaY., FukagawaM., KurokawaK., SeinoY.Decreased 1.25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients.J Clin Invest1993; 92: 1436–43.
16.
PatelS.R., KeH., VanholderR., KoenigR.J., HsuC.H.Inhibition of calcitriol receptor binding to vitamin D response elements by uremic toxins.J Clin Invest1994; 96: 50–9.
17.
SawayaP.B., KoszewskyN.J., QiQ., LangubM.C., Monier-FaugereM.C., MallucheH.H.Secondary hyperparathyroidism and vitamin D receptor binding to vitamin D response elements in rats with incipient renal failure.J Am Soc Nephrol1997; 8: 271–8.
18.
KindmarkA., MelhusH., LjunghallS., LjunggrenO.Inhibitory effects of 9-Cis and all-trans retinoic acid on 1.25(OH)2-vitamin D3 induced bone resorption.Calcif Tissue Int1995; 57: 242–4.
19.
FernandezE., FiblaJ., BetriuA., PiulatsJ.M., AlmirallJ., MontoliuJ.Association between vitamin D receptor gene polymorphism and relative hypoparathyroidism in patients with chronic renal failure.J Am Soc Nephrol1997; 8: 1546–52.
20.
SilverJ., RusselJ., SherwoodL.M.Regulation by vitamin D metabolism of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells.Proc Natl Acad Sci USA1985; 82: 4270–3.
21.
KurokawaK.Calcium-regulating hormones and the kidney.Kidney Int1987; 32: 760–71.
22.
BrickerN.S., SlatopolskyE., ReissE., AvioliL.V.Calcium, phosphate, and bone in renal disease and transplantation.Arch Int Med1969; 123: 543–53.
23.
SlatopolskyE., CalgarS., PennelJ.P.. On the pathogenesis of hyperparathyroidism in chronic renal insufficiency in the dog.J Clin Invest1971; 50: 492–9.
24.
PortaleA.A., HalloranB.P., MorrisR.C.Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men.J Clin Invest1989; 83: 1494–9.
25.
PortaleA.A., BoothB.E., HalloranB.P., MorrisR.C.Effect of dietary phosphorus on circulating concentrations of 1.25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency.J Clin Invest1984; 73: 1580–9.
26.
TessitoreN., VenturiA., AdamiS.. Relationship between serum vitamin D metabolites and dietary intake of phosphate in patients with early renal failure.Min Electrolyte Metab1987; 13: 38–44.
27.
Lopez-HilkerS., DussoA.S., RappN.S., MartinK.J., SlatopolskyE.Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol.Am J Physiol1990; 259: F432–7.
HernandezA., ConceptionM.T., RodriguezM., SalidoE., TorresA.High phosphorus diet increase preproPTH mRNA independent of calcium and calcitriol in normal rats.Kidney Int1996; 50: 1872–8.
30.
AlmadenY., CanalejoA., HernandezA.. Direct effect of phosphorus on parathyroid hormone secretion from whole rat parathyroid gland in vitro.J Bone Miner Res1996; 11: 970–6.
31.
AlmadenY., CanalejoA., AnonG., RodriguezM.The role of arachidonic acid in the stimulation of PTH secretion by high phosphorus.J Am Soc Nephrol1997; 8: 570 (A).
32.
BrownE.M., WilsonR.E., EastmanR.C., PallottaJ., MarynickP.Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure.J Clin Endocrinol Metab1982; 54: 172–9.
33.
LeBoffM.S., ShobackD., BrownE.M.X.. Regulation of parathyroid hormone release and cytosolic calcium by extracellular calcium in dispersed and cultured bovine and pathological human parathyroid cells.J Clin Invest1985; 75: 49–57.
34.
Naveh-ManyT., RahamimovR., LivniN., SilverJ.Parathyroid cell proliferation in normal and chronic renal failure rats: the effect of calcium, phosphate and vitamin D.J Clin Invest1995; 96: 1786–93.
35.
BrownE.M., GambraG., RiccardiR.. Cloning and characterization of extracellular Ca2 ± sensing receptor from bovine parathyroid.Nature1993; 366: 575–80.
36.
PollackM.R., BrownE.M., ChouY-HW. Mutations in the human Ca2-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism.Cell1993; 75: 1297–303.
37.
RamirezJ.A., GoodmanW.G., GornbeinJ.. Direct in vivo comparison of calcium regulated parathyroid hormone secretion in normal volunteers and patients with secondary hyperparathyroidism.J Clin Endocrinol Metab1993; 76: 1489–94.
38.
GoodmanW.G., VeldhuisJ.D., GalesB., JuppnerH., SaluskyIB:Calcium-sensing by the parathyroids in severe secondary hyperparathyroidism before parathyroidectomy.J Am Soc Nephrol1997; 8: 574(A).
39.
EvansonJM:The effect of the infusion of parathyroid extracts in hypocalcemic states.Clin Sci1966; 31: 63–75.
40.
MassryS.G., CoburnJ.W., LeeD.B.N., JowseyJ., KleemanC.R.Skeletal resistance to parathyroid hormone in renal failure. Studies in 195 human subjects.Ann Intern Med1973; 78: 357–64.
41.
MassryS.G., SteinR., GartyJ.. Skeletal resistance to the calcemic action of parathyroid hormone in uremia: role of 1,25(OH)2D3.Kidney Int1976; 9: 467–74.
42.
RodriguezM., Martin-MaloA., MartinezM.E., FelsenfeldA.J., LlachF.Calcemic response to parathyroid hormone in renal failure: role of phosphorus and its effects on calcitriol.Kidney Int1991; 40: 1055–62.
43.
TianJ., SmogorzewskiM., KedesL., MassrySG:PTH-PTHrP receptor mRNA is downregulated in chronic renal failure.Am J Nephrol1994; 14: 41–6.
44.
UreñaP., KubruslyM., MannstadtM.. The renal PTH/PTHrP receptor is downregulated in rats with chronic renal failure.Kidney Int1994; 45: 605–11.
45.
AndressD.L., HowardG.A., BirnbaumR.S.Identification of a low molecular weight inhibitor of osteoblast mitogenesis in uremic plasma.Kidney Int1991; 39: 942–5.
46.
QuarlesD.L., LobaughB., MurphyG.Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia.J Clin Endocrinol Metab1992; 75: 145–50.
47.
FukagawaM., KitaokaM., KurokawaK.Resistance of the parathyroid glands to vitamin D in renal failure: Implications for medical management, Kidney Int1997; 62(Suppl): 60–4.
48.
CannellaG., BonucciE., RollaD.. Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol.Kidney Int1994; 42: 1124–32.
49.
CoenG., MazzaferroS., BonucciE.. Treatment of secondary hyperparathyroidism of predialysis chronic renal failure with low doses of 1.25(OH)2D3: humoral and histomorphometric results.Mineral Electrolyte Metab1986; 12: 375–82.
50.
GoodmanW.G., CoburnJ.W.The use of 1.25-dihydroxyvitamin D3 in early renal failure.Annu Rev Med1992; 43: 227–37.
51.
HamdyN.A., KanisJ.A., BenetonM.N.C.. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure.BMJ1995; 310: 358–63.
52.
RitzE., KusterS., Schmidt-GaykH.. Low-dose calcitriol prevents the rise in 1,84 iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial).Nephrol Dial Transplant1995; 10: 2228–34.
53.
FournierA., IdrissiA., SebertJ.. Preventing renal bone disease in moderate renal failure with CaC03 and 25(OH) vitamin D3.Kidney Int24(Suppl): 178–9.
54.
OkadaK., TakahashiS., YanaiM., MaejimaM., NaguraY., HatanoM.Is administration of vitamin D metabolite needed for the treatment of secondary hyperparathyroidism at the predialytic stage?Nephron1991; 58: 492–3.
55.
JohnsonW.J.Optimum dialysate calcium concentration during maintenance hemodialysis.Nephron1976; 17: 241–58.
56.
MalbertiF., ScanzianiR., CorradiB.. High-dose oral calcitriol and zero calcium peritoneal solutions in CAPD patients with refractory seconday hyperparathyroidism.Nephrol Dial Transplant1994; 9: 1759–64.
57.
MactierR.A., Van StoneJ., CoxA.. Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia.Clin Nephrol1987; 28: 222–6.
58.
De VincenziA., BellazziR.G., SantagostinoM.. High and low-flux acetate free biofiltration: experimental assessment of calcium mass balance and intact parathyroid hormone behaviour.Nephrol Dial Transplant1994; 9: 1305–9.
59.
ArgilesI., CiscartA.Points to remember when selecting dialysate calcium concentration.Nephrol Dial Transplant1995; 10: 451–4.
60.
RitzE., Passlick-DeetjenJ., LippertJ.What is the appropriate dialysate calcium concentration for the dialysis patients.Nephrol Dial Transplant1996; 3(Suppl): 91–5.
61.
FarringtonK., MohammedM.N., NewmanS.P., VargheseZ., MoorheadJ.F.Comparison of radioisotope methods for the measurement of phosphate absorption in normal subjects and in patients with chronic renal failure.Clin Sci1981; 60: 55–63.
62.
RamirezJ.A., EmmettM., WhiteM.G.. The absorption of dietary phosphorus and calcium in hemodialysis patients.Kidney Int1986; 30: 753–9.
63.
WiegmannT.B., KayeM.Malabsorption of calcium and phosphate in chronic renal failure: 32P and 45Ca studies in dialysis patients.Clin Nephrol1990; 34: 35–41.
64.
CannellaG.Moriero E, Rolla D. Practical guidelines for effective treatment of the Osteodystrophic uraemic syndrome with intravenous calcitriol.Nephrol Dial Transplant1996; 3(Suppl): 50–3.
65.
LlachF.The importance of achieving optimal control of serum phosphorus.Nephrol Exchange1996; 6: 1–11.
66.
BurkeS.K., SlatopolskyE.A., GoldbergD.I.RenaGel®, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers.Nephrol Dial Transplant1997; 12: 1640–4.
67.
FischbachM., HamelG.Simeoni U, Geisert J. Phosphate dialytic removal: enhancement of phosphate cellular clearance by biofiltration (with acetate-free buffer dialysate).Nephron1992; 62: 155–60.
68.
LiuS.H., ChuH.I.Studies of calcium and phosphorus metabolism with special reference to pathogenesis and effect of dihy-drotachysterol (AT10) and iron.Medicine1943; 22: 103–61.
69.
BrumbaughP.F., HughesM.R., HausslerM.R.Cytoplasmic and nuclear binding components for 1.25-dihydroxyvitamin D3 in chick parathyroid glands.Proc Natl Acad Sci USA1975; 72: 4871–5.
70.
SlatopolskyE., WeertsC., ThielanJ., HorstR., HarterH., MartinJ.K.Marked suppression of secondary hyperparathyroidism by intravenous administration of 1.25-dihydroxycholecalciferol in uremic patients.J Clin Invest1984; 74: 2136–43.
71.
SwenyP.Optimum route of administration of vitamin D in renal failure.Nephrol Dial Transplant1995; 4(Suppl): 29–32.
72.
ReichelH.Optimum mode of administration of vitamin D in renal failure. Insights from experimental data.Nephrol Dial Transplant1995; 4(Suppl): 33–6.
73.
IndridasonO.S., QuarlesL.D.Oral versus intravenous calcitriol: is the route of administration really important?Current Opinion Nephrol Hypert1995; 4: 307–12.
74.
QuarlesL.D., YohayD.A., CarrolB.A.. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD.Kidney Int1994; 45: 1710–21.
75.
BrownA.J., RitterC.R., FinchJ.L.. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.J Clin Invest1989; 84: 728–32.
76.
PosnerG.H.New vitamin D analogues.Nephrol Dial Transplant1996; 11(Suppl): 32–36.
77.
FinchJ.L., BrownA.J., SlatopolskyE.Differential effects of 1.25-(OH)2D3 and 19-nor-1.25-(OH)2D3 on calcium and phosphate resorption in bone.J Am Soc Nephrol1997; 8: 573(A).
78.
LevineB.S., SingerF.R., BryceG.F., MallonJ.P., MillerO.N., CoburnJ.W.Pharmacokinetics and biologic effects of calcitriol in normal humans.J Lab Clin Med1985; 105: 239–46.
79.
SaluskyI.B., GoodmanW.G., HorstR.. Pharmacokinetics of calcitriol in continuous ambulatory and cycling peritoneal dialysis patients.Am J Kidney Dis1990; 16: 126–32.
80.
CantleyL.K., RusselJ., LettieriD., SherwoodS.M.1.25-dihydroxyvitamin D3 suppresses parathyroid hormone secretion from bovine parathyroid cells in tissue culture.Endocrinology1985; 117: 2114–9.
81.
SeidelA., HerrmanP., GüntherK., MehlsO., Schmidt-GaykH., RitzE.Kinetics of plasma iPTH(1-84) after high dose of calcitriol in uremic patients.Clin Nephrol1993; 39: 210–3.
82.
MessaP., MioniG.Bresadola F, Montanaro D, Risaliti A. Further characterization of persistent hyperparathyroidism in renal transplanted patients.J Am Soc Nephrol1997; 8: 577(A).
83.
ParfittA.M.The hyperparathyroidism of chronic renal failure: a disorder of growth.Kidney Int1997; 52: 3–9.
